SCO-267

• CAT Number: I036137
• CAS Number: 1656261-09-4
• Molecular Formula: C36H46N4O5
• Molecular Weight: 614.77
• Purity: ≥95%
• Synonyms: (3S)-3-cyclopropyl-3-[2-[[1-[2-[2,2-dimethylpropyl-(6-methylpyridin-2-yl)carbamoyl]-5-methoxyphenyl]piperidin-4-yl]methoxy]pyridin-4-yl]propanoic acid
• InChI: InChI=1S/C36H46N4O5/c1-24-7-6-8-32(38-24)40(23-36(2,3)4)35(43)29-12-11-28(44-5)20-31(29)39-17-14-25(15-18-39)22-45-33-19-27(13-16-37-33)30(21-34(41)42)26-9-10-26/h6-8,11-13,16,19-20,25-26,30H,9-10,14-15,17-18,21-23H2,1-5H3,(H,41,42)/t30-/m0/s1
• InChIKey: VVRXREQIOCYUKN-PMERELPUSA-N
• SMILES: CC1=NC(=CC=C1)N(CC(C)(C)C)C(=O)C2=C(C=C(C=C2)OC)N3CCC(CC3)COC4=NC=CC(=C4)C(CC(=O)O)C5CC5

SCO-267 (Cat No.: I036137) is an investigational small-molecule agonist of the bile acid receptor TGR5 (G protein-coupled bile acid receptor 1), which plays a role in energy metabolism, glucose regulation, and inflammation. By activating TGR5, SCO-267 stimulates the release of GLP-1 and other metabolic hormones, enhances insulin sensitivity, and promotes energy expenditure. It is being explored for the treatment of metabolic disorders such as type 2 diabetes and obesity. SCO-267 is primarily used in preclinical and clinical studies to assess TGR5-targeted therapeutic strategies.

Reference

[1]. Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293.
[Content Brief]